Notice of Intent to Sole Source � CARDINAL HEALTH 414, LLC� radiopharmaceuticals
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation NOI-OD-27-000001 in this department, oldest first.
- Oct 13, 2026 · this noticePre-solicitation
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. This procurement is for a purchase order NTE $900,000 for FDA-approved radiopharmaceuticals for patient care by the Nuclear Medicine Division, Department of Radiology and Imaging Sciences at the NIH Clinical Center. CARDINAL HEALTH is a reputed and reliable FDA and US NRC vetted supplier of the required radiopharmaceuticals by the Clinical Center. Based on the past 25 years of contracting with this vendor, this vendor is the only acceptable vendor because … (show all)
they provide a comprehensive list of radiopharmaceuticals that uniquely meets the patient needs of the NIH Clinical Center. They are the only provider that can supply all radiopharmaceuticals that emit gamma, positrons, beta and/or alpha radiations. They also use a patented tungsten delivery system for dispensing the high energy positron radiopharmaceuticals. This system minimizes radiation exposure to the staff and the public, as well as meeting the weight standard that reduces the potential weightlifting injuries to the staff. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 �Simplified Acquisition Procedures, Subpart 13.500 This subpart authorizes the use of simplified procedures for the acquisition of supplies and services in amounts greater than the simplified acquisition threshold but not exceeding $9 million ($15 million for acquisitions as described in 13.500(c)), including options, if the contracting officer reasonably expects, based on the nature of the supplies or services sought, and on market research, that offers will include only commercial products or commercial services. Contracting officers may use any simplified acquisition procedure in this part, subject to any specific dollar limitation applicable to the particular procedure. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to Ryssa.nix@nih.gov by close date. Notice Type: Notice of Intent NAICS Code: 325412 PSC Code: 3650 Posted Date: 10/13/2026 Close Date: 10/19/2026 12pm EST End User IC: Clinical Center POC Name: Ryssa Nix Email Address: Ryssa.nix@nih.gov
Who won similar work
8 award notices on SAM.gov in the last 24 months. Match: Same agency (National Institutes of Health), same NAICS 325412.
| Winner | Awards | Value | Last |
|---|---|---|---|
| SRI INTERNATIONAL Menlo Park CA 94025 USA | 2 | – + 2 shared | Jul 8, 2026 |
| CURIA GLOBAL INC | 1 | – + 1 shared | May 5, 2026 |
| EMINENT SERVICES CORP | 1 | – + 1 shared | Jul 8, 2026 |
| ALCHEM LABORATORIES CORPORATION | 1 | – + 1 shared | May 5, 2026 |
| MRIGLOBAL Kansas City MO 64110 USA | 1 | – + 1 shared | May 5, 2026 |
| MURTY PHARMACEUTICALS, INC. | 1 | – + 1 shared | Jul 8, 2026 |
| KYMANOX CORP | 1 | – + 1 shared | Jul 8, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in.
- Jul 8, 2026KYMANOX CORP$49.9M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
- Jul 8, 2026SRI INTERNATIONAL Menlo Park CA 94025 USA$49.9M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
- Jul 8, 2026MURTY PHARMACEUTICALS, INC.$49.9M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
- Jul 8, 2026EMINENT SERVICES CORP$49.9M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
- May 5, 2026SRI INTERNATIONAL Menlo Park CA 94025 USA$50.0M (shared ceiling)A--Drug Manufacturing and Formulation Program (DMFP)
- May 5, 2026CURIA GLOBAL INC$50.0M (shared ceiling)A--Drug Manufacturing and Formulation Program (DMFP)
- May 5, 2026MRIGLOBAL Kansas City MO 64110 USA$50.0M (shared ceiling)A--Drug Manufacturing and Formulation Program (DMFP)
- May 5, 2026ALCHEM LABORATORIES CORPORATION$50.0M (shared ceiling)A--Drug Manufacturing and Formulation Program (DMFP)
Competitive landscape
For the 7 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.